Dyne Therapeutics (DYN) Net Cash Flow (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Net Cash Flow of -$77.0 million for Q2 2026, down 699.23% year-over-year from $12.8 million in Q2 2025, and up 45.12% quarter-over-quarter from -$140.2 million in Q1 2026.
Dyne Therapeutics (DYN) Net Cash Flow (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Net Cash Flow for 8 consecutive years, with -$77.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Cash Flow fell 699.23% year-over-year to -$77.0 million; the TTM figure through Jun 2026 stood at $191.5 million (up 255.57% YoY), while the FY2025 annual figure was $458.3 million, up 46.23% from the prior year.
- Net Cash Flow advanced to -$77.0 million in Q2 2026 per DYN's latest filing, from -$140.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $336.2 million in Q2 2024 and bottomed at -$140.2 million in Q1 2026.
- Historically, Net Cash Flow has averaged $26.4 million across 5 years, with a median of $130000.0 in 2022.
- On a YoY basis, Net Cash Flow climbed as much as 2589.4% in 2024 and fell as far as 1016.35% in 2024.
- Dyne Therapeutics' Net Cash Flow stood at $27.2 million in 2022, then sank by 131.79% to -$8.7 million in 2023, then plunged by 1016.35% to -$96.7 million in 2024, then jumped by 431.01% to $320.1 million in 2025, then sank by 124.04% to -$77.0 million in 2026.
- Business Quant data shows DYN's Net Cash Flow at -$77.0 million in Q2 2026, -$140.2 million in Q1 2026, and $320.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | -76.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -76.97 Mn |
| Jun 30, 2026 | -76.97 Mn |
| Mar 31, 2026 | -140.25 Mn |
| Mar 31, 2026 | -140.25 Mn |
| Dec 31, 2025 | 320.12 Mn |
| Dec 31, 2025 | 320.12 Mn |
| Sep 30, 2025 | 88.58 Mn |
| Sep 30, 2025 | 88.58 Mn |
| Jun 30, 2025 | 12.85 Mn |
| Jun 30, 2025 | 12.85 Mn |
| Mar 31, 2025 | 36.81 Mn |
| Mar 31, 2025 | 36.81 Mn |
| Dec 31, 2024 | -96.71 Mn |
| Dec 31, 2024 | -96.71 Mn |
| Sep 30, 2024 | -76.02 Mn |
| Sep 30, 2024 | -76.02 Mn |
| Jun 30, 2024 | 336.17 Mn |
| Jun 30, 2024 | 336.17 Mn |
| Mar 31, 2024 | 150.01 Mn |
| Mar 31, 2024 | 150.01 Mn |